Xcout Intel
Mironid
Mironid Limited is a privately held drug discovery company founded in 2015 and headquartered in Glasgow, Scotland. The patient-focused company develops innovative therapeutics to improve the treatment of various medical conditions.
Subscribe to see Mironid’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mironid at a glance
Mironid is a biotech company headquartered in United Kingdom, founded in 2014. Its most recent funding round, Series A extension, raised $43.9M in August 2026. Xcout tracks 2 named people at Mironid, including Neil Wilkie (CEO).
Mironid leadership
- Neil WilkieCEO
- Miles HouslayProfessor
Mironid funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A extension | $43.9M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Mironid news
Investors
Mironid competitors
A few of Mironid's closest competitors — see the full list of competitors and alternatives →
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
Halda Therapeutics is a life sciences and drug discovery company based in New Haven, Connecticut, focused on developing targeted therapeutics.
Harmonic Discovery is a drug discovery company founded in 2021 and headquartered in New York City. The company leverages machine learning and precision pharmacology to develop therapeutics for complex diseases.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Mesentech Inc. is an active for-profit biotechnology company focused on drug pipelines, therapeutic areas, and proprietary technology platforms. Headquartered in Vancouver, British Columbia, Canada, the company operates with a small team specializing in clinical research and development.
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Get Mironid's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mironid in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access